BillionToOne (BLLN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 Jun, 2026Opening remarks and agenda
CEO welcomed stockholders and introduced the meeting, confirming the virtual format and participant rights.
General Counsel called the meeting to order, confirmed notice and proxy materials were distributed, and outlined the agenda.
Board and executive committee updates
Election of two Class I directors, Oguzhan Atay and Akshay Rai, to serve until the 2029 annual meeting was on the agenda.
Corporate governance
Quorum was confirmed, enabling the meeting to transact business.
Inspector of election's oath was filed with the meeting minutes.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BillionToOne
- Single molecule diagnostics innovation fuels rapid growth, profitability, and clinical impact.BLLN
46th Annual William Blair Growth Stock Conference2 Jun 2026 - 2025 revenue doubled, margins rose, and 2026 guidance increased to $430–$445M.BLLN
Q4 202516 May 2026 - Q1 2026 revenue rose 84% to $108.4M, net income hit $18M, and guidance was raised.BLLN
Q1 202612 May 2026 - 2026 meeting to elect directors, ratify auditor, and review enhanced executive compensation.BLLN
Proxy filing22 Apr 2026 - Election of directors and auditor ratification headline the June 2026 virtual annual meeting.BLLN
Proxy filing21 Apr 2026 - Single-molecule NGS innovation drives rapid growth, high margins, and expanding market share.BLLN
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Q3 2025 revenue up 117% YoY, 70% gross margin, and GAAP profitability achieved.BLLN
Q3 202510 Dec 2025 - Rapidly growing diagnostics firm with advanced technology, strong margins, and large market potential.BLLN
Registration Filing29 Nov 2025 - IPO offers 3.85M shares at $49–$55, funding growth in $100B+ precision diagnostics.BLLN
Registration Filing17 Oct 2025